A series of monopyrrolinone-based HIV-1 protease inhibitors possessing rationally designed P2' side chains have been synthesized and evaluated for activity against wild-type HIV-1 protease. The most potent inhibitor displays subnanomolar potency in vitro for the wild-type HIV-1 protease. Additionally, the monopyrrolinone inhibitors retain potency in cellular assays against clinically significant mutant forms of the virus. X-ray structures of these inhibitors bound in the wild-type enzyme reveal important insights into the observed biological activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bmcl.2005.11.011 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!